GSK-Vir therapy works against Omicron sub-variant, data suggests, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Based on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain activity against the BA.2 variant, which is in line with all other variants of concern and interest., Based on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain activity against the BA.2 variant, which is in line with all other variants of concern and interest., , Read More